44 results
8-K
ALLO
Allogene Therapeutics Inc
31 Jan 24
Entry into a Material Definitive Agreement
12:00am
killer (NK) cell products from induced pluripotent stem cells directed at certain chimeric antigen receptor (CAR) targets for initial application in non … to add certain additional specified targets to the exclusive license in exchange for an agreed upon per-target option fee.
Under the Amended
8-K
EX-99.1
ynzh9ou4gm
2 Nov 23
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
4:03pm
8-K
fi8b0hncuq4w6 gke
29 Nov 22
Other Events
3:33pm
8-K
EX-99.1
g2penm ne
2 Nov 22
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
4:16pm
PRE 14A
jm3pscys f5u7170
14 Apr 22
Preliminary proxy
4:10pm
8-K
EX-99.1
ye325h
4 Nov 21
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
4:13pm